Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity

Cardiomyopathy Due to Drug Clinical Trial

Official title: Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity: Clinical and Prognostic Implications

Status Recruiting

Clinical Trial Summary

This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment

Clinical Trial Description

The main aim of this interventional study is to evaluate biochemical and imaging markers of fibrosis in patients who had previously developed AIC during or after anthracycline-containing therapy. Anthracycline-induced cardiomyopathy (AIC) is define as a reduction in Left Ventricular Ejection Fraction (LVEF) >10% units from baseline and below 50%, assessed by echocardiography, during or after anthracycline-containing therapy. All patients will undergo: - at time 0 - an echocardiogram with LVEF evaluation (biplane method) - a single blood sample. - at time 1 - a Cardiac Magnetic Resonance (RMC) with contrast agent (T1 mapping technique) (time 1 = within 72 hours from blood sample). ;

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy Due to Drug
• Cardiotoxicity

• NCT number: NCT06331806
• Study type: Interventional
• Source: European Institute of Oncology
• Contact: Daniela Cardinale, MD
• Phone: +39 0257489748
• Email: daniela.cardinale@ieo.it
• Status: Recruiting
• Phase: N/A
• Start date: February 22, 2018
• Completion date: December 31, 2024